Hakimi, A. Ari http://orcid.org/0000-0002-0930-8824
Attalla, Kyrollis
DiNatale, Renzo G.
Ostrovnaya, Irina
Flynn, Jessica
Blum, Kyle A.
Ged, Yasser
Hoen, Douglas
Kendall, Sviatoslav M.
Reznik, Ed http://orcid.org/0000-0002-6511-5947
Bowman, Anita
Hwee, Jason
Fong, Christopher J.
Kuo, Fengshen http://orcid.org/0000-0003-1797-2896
Voss, Martin H. http://orcid.org/0000-0003-0551-5807
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Motzer, Robert J. http://orcid.org/0000-0001-6925-2327
Article History
Received: 19 December 2019
Accepted: 23 July 2020
First Online: 20 August 2020
Competing interests
: A.A.H. corresponding author, certifies that all conflicts of interest, including specific financial interests, relationships, and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: T.A.C. is a paid consultant for Bristol-Myers Squibb and Illumina, reports receiving commercial research grants from AstraZeneca, Illumina, Pfizer, and BMS, and holds ownership interest (including patents) in Gritstone. M.H.V. reports honoraria from Novartis; consulting/advisory role for Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis, and Pfizer; research funding from Pfizer, Bristol-Myers Squibb, and Genentech/Roche; and travel, accommodations, and expenses from Eisai, Novartis, and Takeda. R.J.M. reports grants and personal fees from Pfizer, Novartis, Eisai, Genentech/Roche; personal fees from Exelixis, Merck, Lilly, and Incyte; and grants from BMS outside the submitted work. The remaining authors declare no conflict of interest.